ArticleThe Prostate2018
FOXP3
Article in The Prostate, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 56 citations in OpenAlex.
- Use of Aspirin and Statins in Relation to Inflammation in Benign Prostate Tissue in the Placebo Arm of the Prostate Cancer Prevention Trial.Cancer prevention research (Philadelphia, Pa.) · 2020Trial
- Gene expression profiles in benign prostate tissue reflect tumor proximity, grade, and molecular subtype.Journal of translational medicine · 2026Article
- Revolutionizing cancer care: Bioprinting prostate cancer stem cells for targeted treatments.World journal of clinical oncology · 2025Review
- PD-L1 and FOXP3 expression in high-grade squamous intraepithelial lesions of the anogenital region.Oncotarget · 2025Article
- Article
- Patterns of B-cell lymphocyte expression changes in pre- and post-malignant prostate tissue are associated with prostate cancer progression.Cancer medicine · 2024Article
- CACYBP knockdown inhibits progression of prostate cancer via p53.Journal of cancer research and clinical oncology · 2023Article
- A Five Glutamine-Associated Signature Predicts Prognosis of Prostate Cancer and Links Glutamine Metabolism with Tumor Microenvironment.Journal of clinical medicine · 2023Article
- The Role ofMicroorganisms · 2022Review
- Anti-tumor activity of a T-helper 1 multiantigen vaccine in a murine model of prostate cancer.Scientific reports · 2022Article
- Inflammation and Prostate Cancer: A Multidisciplinary Approach to Identifying Opportunities for Treatment and Prevention.Cancers · 2022Review
- Cutibacterium acnes Induces the Expression of Immunosuppressive Genes in Macrophages and is Associated with an Increase of Regulatory T-Cells in Prostate Cancer.Microbiology spectrum · 2021Article
- Immunophenotype Rearrangement in Response to Tumor Excision May Be Related to the Risk of Biochemical Recurrence in Prostate Cancer Patients.Journal of clinical medicine · 2021Article
- Hormonal Therapy for Prostate Cancer.Endocrine reviews · 2021Review
- Immune Checkpoints, Inhibitors and Radionuclides in Prostate Cancer: Promising Combinatorial Therapy Approach.International journal of molecular sciences · 2021Review
- Effects of miR-103a-3p Targeted Regulation of TRIM66 Axis on Docetaxel Resistance and Glycolysis in Prostate Cancer Cells.Frontiers in genetics · 2021Article
- Immune-Related Genes Are Prognostic Markers for Prostate Cancer Recurrence.Frontiers in genetics · 2021Article
- The Anticancer Potential of Maslinic Acid and Its Derivatives: A Review.Drug design, development and therapy · 2021Review
- Long non-coding RNA NORAD contributes to the proliferation, invasion and EMT progression of prostate cancer via the miR-30a-5p/RAB11A/WNT/β-catenin pathway.Cancer cell international · 2020Article
- Mirage or long-awaited oasis: reinvigorating T-cell responses in pancreatic cancer.Journal for immunotherapy of cancer · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe tumor promoting or counteracting effects of the immune response to cancer development are thought to be mediated to some extent by the infiltration of regulatory T cells (T
methodsStudy subjects were 102 men consecutively diagnosed with localized prostate cancer undergoing radical prostatectomy and 38 men diagnosed with bladder cancer undergoing cystoprostatectomy without prostate cancer at the pathological examination. Whole mount sections from all patients were evaluated for the epithelial and stromal expression of CD4
resultsIn men with prostate cancer, similarly high numbers of stromal CD4
conclusionsOur results may suggest a possible pathway through which PAH develops directly into prostate cancer in the presence of CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.